Hata, Aaron N <br/><br/>
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.  [electronic resource] 

 -  Cancer research  Jun 2014 
 - 3146-56 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-13-3728  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Apoptosis Regulatory Proteins--genetics<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Line, Tumor<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>MAP Kinase Signaling System--drug effects<br/>Mice<br/>Mice, Nude<br/>Mitochondria--drug effects<br/>Mutation<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-bcl-2--genetics<br/>Signal Transduction--drug effects<br/>bcl-X Protein--genetics<br/>ras Proteins--genetics